XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
License and Collaboration Agreements - Narrative (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 96 Months Ended
May 28, 2021
USD ($)
Aug. 03, 2020
USD ($)
shares
Jan. 07, 2018
USD ($)
Oct. 31, 2014
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Sep. 30, 2022
USD ($)
Oct. 01, 2014
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Expenses related to collaboration agreement         $ 131,076,000 $ 116,109,000 $ 390,391,000 $ 354,755,000      
Income tax expense         254,000 3,299,000 254,000 3,299,000      
Unrealized loss on available-for-sale investments         (1,000) (6,000) (5,712,000) (164,000)      
BeiGene Agreement                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Non-refundable, non-creditable up-front fee     $ 10,000,000                
Milestone payments     $ 123,000,000                
Termination of contract, period after first commercial sale of product     10 years                
Period required for notice of termination of contract     60 days                
Performance obligation, compensation to be earned     $ 500,000                
Milestone payments earned         0   0        
Royalty revenue         0 0 0 0      
BeiGene Agreement | Maximum                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Royalty percentage rate (up to)     0.20                
BeiGene Agreement | Licenses of Intellectual Property                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Performance obligation, compensation to be earned     $ 9,500,000                
Milestone payments earned           5,000,000   5,000,000      
BeiGene Agreement | Manufacturing Supply Services                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue recognized         0 100,000 0 100,000      
Pfizer Agreement                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Termination of contract, period after first commercial sale of product       10 years              
Period required for notice of termination of contract       60 days              
Pfizer Agreement | adagrasib                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Expenses related to collaboration agreement         0 0 0 5,000,000      
Pfizer Agreement | Development Milestone Payments                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Potential development milestone payments                     $ 9,300,000
Development milestone payments                   $ 9,500,000  
Pfizer Agreement | Sales Milestone Payments                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Potential development milestone payments                     $ 337,000,000
ORIC Pharmaceuticals Agreement                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Stock received as part of stock issuance and license agreements (shares) | shares   588,235                  
License agreement, period of transfer restrictions   18 months                  
License agreement, period of agreement after first commercial sale   10 years                  
ORIC Pharmaceuticals Agreement | Level 3                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
One-time non-cash payment   $ 11,400,000                  
Zai Agreement                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Period required for notice of termination of contract 12 months                    
Milestone payments earned         5,000,000 0   0      
Termination of contract, period after first commercial sale of product 10 years                    
Up-front fee received $ 65,000,000                    
Transaction price of arrangement 66,600,000                    
Unrealized loss on available-for-sale investments         300,000   300,000        
Zai Agreement | Licenses of Intellectual Property                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue recognized                 $ 66,600,000    
Income tax expense                 $ 3,300,000    
Zai Agreement | Manufacturing Supply Services                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue recognized         300,000 0 1,400,000 0      
Zai Agreement | Milestone Payments | adagrasib                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Milestone payments earned             5,000,000        
Zai Agreement | Sales Milestone Payments                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue from performance obligation expected to be earned 180,000,000                    
Zai Agreement | Development and Regulatory Milestone Payments                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue from performance obligation expected to be earned $ 93,000,000                    
Zai Agreement | Royalties                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Royalty revenue         $ 0 $ 0 $ 0 $ 0